fMRI를 유도 경 두개 자기 자극하는 동안 기록 된 EEG 데이터에서 시각 유발 전위를 추출

Executive Industry Relevance

Establishing causal links between defined brain regions and electrophysiological responses is critical for target validation in neuroscience drug discovery. This method enables precise interrogation of cortical networks using fMRI-guided TMS and high-temporal EEG readouts, supporting mechanistic de-risking of therapeutic hypotheses. By isolating neural activity from stimulation artifacts, it provides quantitative, reproducible data for early target confidence assessment.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables causal testing of whether fMRI-defined brain regions modulate specific ERP components, supporting target hypothesis validation.
• Operational Value: Provides a reproducible workflow for linking spatial brain targets with temporal electrophysiological readouts.
• Predictive Value: Generates quantifiable ERP amplitude changes as functional readouts for pathway engagement.

Screening & Assay Development

• Assay Readiness: Produces standardized ERP templates from blank-screen trials to quantify and subtract TMS artifacts, enabling clean signal extraction.
• Quantitative Output: Delivers time-locked ERP measurements (e.g., N1 component amplitude) as dose-responsive readouts for target modulation.
• Scalability: Supports repeated blocks across cortical targets with consistent artifact removal, facilitating multi-target screening.

Translational & Preclinical Research

• Translational Continuity: Bridges fMRI-defined targets with EEG biomarkers, enabling cross-species validation of network engagement.
• Mechanistic De-risking: Dissociates overlapping cognitive processes (e.g., face vs. body perception) by linking distinct ERP components to separable neural networks.
• Predictive Confidence: Uses ERP amplitude changes as functional proxies for target-specific network modulation, reducing ambiguity in target selection.

Pipeline & Workflow Integration

The method fits within early discovery workflows where spatial targeting (fMRI), perturbation (TMS), and temporal readout (EEG) are integrated to validate target engagement before lead identification.

• Discovery Biology: Supports hypothesis-driven interrogation of cortical targets by measuring causal effects on neural dynamics via ERP modulation.
• Screening: Enables assay development through standardized TMS artifact subtraction, yielding reliable ERP readouts across stimulus conditions.
• Analytics: Provides quantitative, time-resolved ERP data (e.g., N1 peak amplitude) for comparing target-specific neural responses.
• Translational Research: Aligns fMRI-defined targets with EEG-derived biomarkers, supporting biomarker qualification for preclinical continuity.
• Enterprise Reuse: Establishes a standardized neurophysiological platform for repeated use across targets and cognitive paradigms.

Operational & Enterprise Impact

• Scientific Value: Reduces mechanistic ambiguity by isolating target-specific ERP changes from non-specific TMS effects.
• Operational Value: Ensures reproducibility through artifact subtraction protocols and coregistration standards.
• Strategic Value: Improves go/no-go decisions by providing causal, quantitative neural readouts for target validation.
• Portfolio Impact: Enables risk-adjusted prioritization of targets based on demonstrated network-specific ERP modulation.

Implementation Considerations

• Expertise in fMRI experimental design, TMS safety, and EEG signal processing is required.
• Instrumentation includes MRI-compatible TMS systems, high-sampling EEG (≥1 kHz), and stereotactic navigation.
• Cross-team standardization depends on shared protocols for artifact window definition, template averaging, and coregistration.
• Adaptation to other models requires validation of homologous targets and ERP components.
• Practical limitations include residual artifact correction and subject movement sensitivity during combined TMS-EEG recording.

Biopharma FAQs